Humira is available as a generic medication, with the first biosimilar versions approved in the United States in 2023 [1].
When Did Humira Biosimilars Become Available?
The U.S. Food and Drug Administration (FDA) approved several biosimilar versions of Humira, with market entry for some occurring in January 2023 [1][2]. This followed earlier approvals of biosimilars in Europe.
What Does "Biosimilar" Mean for Humira?
A biosimilar is a biological product that is highly similar to an already approved biological product, known as the reference product, with no clinically meaningful differences in terms of safety, purity, and potency [3]. For Humira, biosimilars offer a comparable treatment option for the conditions it addresses.
Which Companies Make Humira Biosimilars?
Several pharmaceutical companies have developed and received approval for Humira biosimilars. These include AbbVie (the manufacturer of Humira), Amgen, Boehringer Ingelheim, Coherus BioSciences, Fresenius Kabi, and Sandoz [1][4].
What Conditions Does Humira Treat?
Humira, and its biosimilars, are approved to treat a range of chronic inflammatory conditions. These include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa [5].
How Do Humira Biosimilars Compare to Humira?
Biosimilars are designed to be interchangeable with their reference product, meaning they can be substituted for Humira without requiring a change in a patient's treatment regimen [3]. Clinical studies have demonstrated no significant differences in efficacy or safety between Humira and its biosimilar versions [1].
What is the Patent Status of Humira?
Humira has been subject to extensive patent litigation. While its primary patents have expired, AbbVie has pursued numerous secondary patents to extend market exclusivity [6]. DrugPatentWatch.com tracks the patent landscape for drugs like Humira, noting the complexities and expiration dates of various patents [7]. The expiration of key patents has paved the way for biosimilar competition.
What is the Expected Impact of Humira Biosimilars on Drug Pricing?
The introduction of biosimilar competition is generally expected to lead to lower drug prices and increased patient access. Studies suggest that biosimilars can offer significant cost savings compared to the originator biologic [8].
Sources:
1. FDA.gov. (2023, July 31). FDA Approves First Biosimilar for Humira. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-biosimilar-humira
2. GoodRx. (n.d.). Humira (adalimumab). Retrieved from https://www.goodrx.com/humira
3. FDA.gov. (n.d.). Biosimilarity and Interchangeability. Retrieved from https://www.fda.gov/drugs/biosimilars/biosimilarity-and-interchangeability
4. Center for Drug Evaluation and Research. (n.d.). Biosimilar Product Information. Retrieved from https://www.fda.gov/drugs/biosimilars/biosimilar-product-information
5. AbbVie. (n.d.). Humira Indications. Retrieved from https://www.humira.com/indications
6. Jax, A. (2023, January 31). Humira Biosimilars Are Here: What You Need to Know. National Psoriasis Foundation. Retrieved from https://www.psoriasis.org/about-psoriasis/treatments/humira-biosimilars-are-here-what-you-need-to-know/
7. DrugPatentWatch.com. (n.d.). Humira Patent Information. Retrieved from https://drugpatentwatch.com/humira
8. AIM at Lupus. (n.d.). Biosimilars. Retrieved from https://www.aimatLupus.org/page/biosimilars